News
Bristol-Myers Squibb hepatitis C bet has not paid off
www.philly.com
[Philadelphia Inquirer (blog)] - “Bristol-Myers paid a fortune for a pearl that turns out to be fake,” Erik Gordon, a University of Michigan business professor who follows the health industry, told Bloomberg, referring to the company's “string of pearls” name for its acquisition strategy.
Google News: Braly's departure occurred sooner than many expected
[Indianapolis Business Journal] - Erik Gordon, a University of Michigan business professor who follows the health-care industry, predicted in mid-August that Braly had "bought herself some time because it would be unusual to remove a CEO in the middle of a major acquisition." But with
WellPoint's CEO Braly Resigns Amid Shareholder Criticism
www.bloomberg.com
[Bloomberg] - “They need a CEO who has demonstrated by his or her experience that they have the expertise to run a company the size that WellPoint will be, and they need them sooner rather than later,” said Erik Gordon, a professor at the University of Michigan's
Coupons an incentive to stick with brand-name drugs
seattletimes.com
[The Seattle Times] - "On a big drug, every day that you can delay the sales drop is a happy day at the drug company," says Erik Gordon, a professor at the University of Michigan's Ross School of Business who follows the drug industry. Developing drugs requires up to a
sorted by relevance / date